Exploratory study for biomarkers to predict efficacy and toxicity to Sorafenib in patients with advanced hepatocellular carcinoma

Trial Profile

Exploratory study for biomarkers to predict efficacy and toxicity to Sorafenib in patients with advanced hepatocellular carcinoma

Recruiting
Phase of Trial: Phase II

Latest Information Update: 09 Jun 2015

At a glance

  • Drugs Sorafenib (Primary)
  • Indications Liver cancer
  • Focus Adverse reactions; Biomarker; Pharmacodynamics; Therapeutic Use
  • Most Recent Events

    • 07 Sep 2012 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top